Skip to main content
Springer Nature Link
Log in

Use of mABs for COVID-19 increases risk of hepatotoxicity and neutropenia

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Htet H, et al. Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis British Journal of Clinical Pharmacology : 6 Mar 2025. Available from: URL: https://doi.org/10.1002/bcp.70025

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Use of mABs for COVID-19 increases risk of hepatotoxicity and neutropenia. Reactions Weekly 2050, 12 (2025). https://doi.org/10.1007/s40278-025-78982-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-025-78982-2